Canaccord analyst William Plovanic raised the firm’s price target on TransMedics (TMDX) to $142 from $129 and keeps a Buy rating on the shares. The firm updated its model to reflect their findings where they identified potential revenue upside of about 6%-10% and tightened up their historical revenue model as well. In our updated revenue model, they recalculated the components of the company’s service revenues (NOP and logistics) for each organ, but the total revenues per organ have not changed. The company has a rare combination of revenue and earnings growth for a company of this market cap.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- Strong Financial Outlook: TransMedics Group’s Surpassing Sales and EPS Forecasts
- TransMedics Group: Strong Growth in Organ Care and Aviation Services Justifies Buy Rating
- TransMedics Group: Hold Rating Amid Ambiguous Job Posting Trends
- TransMedics price target raised to $150 from $130 at Oppenheimer
- TransMedics price target raised to $145 from $125 at Piper Sandler